TY - JOUR
T1 - The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the manchester driving behavior questionnaire
AU - Biederman, Joseph
AU - Fried, Ronna
AU - Hammerness, Paul
AU - Surman, Craig
AU - Mehler, Bruce
AU - Petty, Carter R.
AU - Faraone, Stephen V.
AU - Miller, Carolyn
AU - Bourgeois, Michelle
AU - Meller, Benjamin
AU - Godfrey, Kathryn M.
AU - Baer, Lee
AU - Reimer, Bryan
N1 - Funding Information:
This study was funded by Shire Pharmaceuticals, Inc. The study sponsor had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The authors acknowledge Dr. Eric Mick for statistical analysis of data in this study.
Funding Information:
J.B. is currently receiving research support from the following sources: ElMindA, Janssen, McNeil, Next Wave Pharmaceuticals, and Shire. In 2011, he gave a single unpaid talk for Juste Pharmaceuticals (Spain), received honoraria from the Massachusetts General Hospital (MGH) Psychiatry Academy for a tuition-funded continuing medical education (CME) course, and received an honorarium for presenting at an international scientific conference on ADHD. He also received an honorarium from Cambridge University Press for a chapter publication. He received departmental royalties for a copyrighted rating scale used for ADHD diagnoses, paid by Eli Lilly, Shire, and AstraZeneca; these royalties are paid to the Department of Psychiatry at MGH. In 2010, he received a speaker's fee from Fundación Dr. Manuel Camelo A.C., provided single consultations for Shionogi Pharma, Inc. and Cipher Pharmaceuticals, Inc., and received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In 2009, he received a speaker's fee from the following sources: Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, he received research support, consultation fees, or speaker's fees from the following additional sources: Abbott, Alza, AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Eisai, Forest, Glaxo, Gliatech, Janssen, McNeil, Merck, National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), National Institute on Drug Abuse (NIDA), New River, National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Novartis, Noven, NeuroSearch, Organon, Otsuka, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc., and Wyeth.
PY - 2012/12
Y1 - 2012/12
N2 - Purpose: Young adults with ADHD have been shown to be at increased risk for impairment in driving behaviors. Although stimulant medications have proven efficacy in reducing ADHD symptomatology, there is limited knowledge as to their effects on driving behavior. The focus of this report is on assessing the impact of lisdexamfetamine dimesylate (LDX) on driving behaviors in young adults with ADHD using a validated driving behavior questionnaire. Methods: This assessment was carried out in the context of a randomized, double-blind, 6-week, placebo-controlled, parallel-design study of LDX versus placebo. Subjects were 61 outpatients of both sexes, 18-26 years of age, who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for ADHD. Subjects were randomized to receive LDX or placebo for 6 weeks. Driving behavior was assessed at baseline and at the end of treatment using a U.S. version of the Manchester Driving Behavior Questionnaire (DBQ). Results: Highly significant improvements were documented on LDX, over placebo, in driving behaviors assessed through the DBQ in measures of driving errors, driving lapses, and a trend toward fewer driving violations. There were no meaningful associations between these DBQ results and previously documented changes in a laboratory driving simulation paradigm or with improvement in symptoms of ADHD assessed through the ADHD rating scale. Conclusions: LDX treatment was associated with significant improvements in self-reported driving behaviors that were independent of improvement in symptoms of ADHD. These results suggest that LDX may reduce behaviors associated with driving risks in young adults with ADHD.
AB - Purpose: Young adults with ADHD have been shown to be at increased risk for impairment in driving behaviors. Although stimulant medications have proven efficacy in reducing ADHD symptomatology, there is limited knowledge as to their effects on driving behavior. The focus of this report is on assessing the impact of lisdexamfetamine dimesylate (LDX) on driving behaviors in young adults with ADHD using a validated driving behavior questionnaire. Methods: This assessment was carried out in the context of a randomized, double-blind, 6-week, placebo-controlled, parallel-design study of LDX versus placebo. Subjects were 61 outpatients of both sexes, 18-26 years of age, who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for ADHD. Subjects were randomized to receive LDX or placebo for 6 weeks. Driving behavior was assessed at baseline and at the end of treatment using a U.S. version of the Manchester Driving Behavior Questionnaire (DBQ). Results: Highly significant improvements were documented on LDX, over placebo, in driving behaviors assessed through the DBQ in measures of driving errors, driving lapses, and a trend toward fewer driving violations. There were no meaningful associations between these DBQ results and previously documented changes in a laboratory driving simulation paradigm or with improvement in symptoms of ADHD assessed through the ADHD rating scale. Conclusions: LDX treatment was associated with significant improvements in self-reported driving behaviors that were independent of improvement in symptoms of ADHD. These results suggest that LDX may reduce behaviors associated with driving risks in young adults with ADHD.
KW - ADHD
KW - Driving
KW - Driving behavior questionnaire
KW - Youth
UR - https://www.scopus.com/pages/publications/84869495491
U2 - 10.1016/j.jadohealth.2012.03.005
DO - 10.1016/j.jadohealth.2012.03.005
M3 - Article
C2 - 23174471
AN - SCOPUS:84869495491
SN - 1054-139X
VL - 51
SP - 601
EP - 607
JO - Journal of Adolescent Health
JF - Journal of Adolescent Health
IS - 6
ER -